- Conditions
- Gastric Cancer, Esophageal Cancer, Stomach Cancer, Esophagus Cancer, Gastroesophageal Junction Cancer
- Interventions
- CA-4948, Nivolumab, Pembrolizumab, Trastuzumab, mFOLFOX7
- Drug · Biological
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced May 21, 2026, 7:23 PM EDT